Matsukida Akira, Imai Hisao, Shiono Ayako, Ryuno Yasuhiro, Hashimoto Kosuke, Miura Y U, Endo Satoshi, Okazaki Shohei, Yamaguchi O U, Mouri Atsuto, Abe Takanori, Kaira Kyoichi, Kobayashi Kunihiko, Kato Shingo, Kagamu Hiroshi
Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
Anticancer Res. 2025 Feb;45(2):733-741. doi: 10.21873/anticanres.17461.
BACKGROUND/AIM: Amrubicin is recognized as a second-line treatment for refractory small-cell lung cancer (SCLC) and is administered immediately after chemotherapy; however, it has not been evaluated in patients with recurrent SCLC following chemoradiotherapy (CRT). This study aimed to examine the activity and safety of amrubicin monotherapy in patients with relapsed SCLC previously treated with CRT.
This retrospective study evaluated patients with relapsed SCLC who had been previously treated with CRT, followed by amrubicin monotherapy between April 2007 and June 2021. The clinical efficacy and toxicity were assessed.
Overall, 30 patients (20 men and 10 women) were enrolled. The response rate was 50.0% [95% confidence interval (CI)=33.1-66.8%]. The median progression-free survival and overall survival from the first amrubicin treatment was 4.1 months (95%CI=2.3-6.0 months) and 13.5 months (95%CI=7.5-16.0 months), respectively. Grade ≥3 hematological adverse events occurred as follows: decreased white blood cells in 63.3% of patients, decreased neutrophil count in 70.0%, and febrile neutropenia in 10.0%. Grade 3 pneumonitis was observed in one patient. No treatment-related deaths occurred.
Amrubicin is both feasible and effective in patients with relapsed SCLC who were previously treated with CRT. The efficacy and toxicity of amrubicin in this study were consistent with those of previous reports, indicating that amrubicin retained its effectiveness post-CRT. Consequently, amrubicin following CRT may be the optimal chemotherapeutic choice for patients with relapsed limited-disease SCLC.
背景/目的：氨柔比星被认为是难治性小细胞肺癌（SCLC）的二线治疗药物，在化疗后立即给药；然而，其在接受放化疗（CRT）后复发的SCLC患者中尚未得到评估。本研究旨在探讨氨柔比星单药治疗先前接受过CRT的复发性SCLC患者的活性和安全性。
本回顾性研究评估了2007年4月至2021年6月期间先前接受过CRT，随后接受氨柔比星单药治疗的复发性SCLC患者。评估了临床疗效和毒性。
总共纳入了30例患者（20例男性和10例女性）。缓解率为50.0%[95%置信区间（CI）=33.1-66.8%]。从首次氨柔比星治疗开始计算的中位无进展生存期和总生存期分别为4.1个月（95%CI=2.3-6.0个月）和13.5个月（95%CI=7.5-16.0个月）。≥3级血液学不良事件的发生情况如下：63.3%的患者白细胞减少，70.0%的患者中性粒细胞计数减少，10.0%的患者发生发热性中性粒细胞减少。1例患者出现3级肺炎。未发生与治疗相关的死亡。
氨柔比星在先前接受过CRT的复发性SCLC患者中既可行又有效。本研究中氨柔比星的疗效和毒性与先前报告一致，表明氨柔比星在CRT后仍保持有效性。因此，CRT后使用氨柔比星可能是复发的局限性疾病SCLC患者的最佳化疗选择。
